

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: April 25, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated April 25, 2017, titled Zydus receives final approval from the USFDA for Olmesartan Medoxomil Tablets.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above

Zydus receives final approval from the USFDA for Olmesartan Medoxomil Tablets

Ahmedabad, 25 April 2017

Zydus Cadila has received the final approval from the USFDA to market Olmesartan Medoxomil Tablets in strengths of 5 mg, 20 mg and 40 mg. This is a day one approval after the expiry of 181 day exclusivity.

The drug is an anti-hypertensive and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Olmesartan is \$ 982 million (*IMS MAT February 2017*).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
